Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection

Zhang, Jing; Chen, Chen; Li, Anning; Jing, Weiqiang; Sun, Ping; Huang, Xingyi; Liu, Yingchao; Zhang, Shengchang; Du, Wei; Zhang, Rui; Liu, Ying; Gong, Aihua; Wu, Jibiao; Jiang, Xinyi

doi:10.1038/s41565-020-00843-7

Cited by 205 publications

(168 citation statements)

References 34 publications

Supporting

Mentioning

164

Contrasting

Order By: Relevance

“…Very recently, hydrogels have been explored and employed in immune checkpoint blockade therapy against various tumors, 387 even for cold tumor. 388 Additionally, some smart nucleic acid-based hydrogels also show great potential for non-invasive tumor PTT. Zhang et al designed a PDA-coated nucleic acid nano-gel as a siRNA-mediated therapeutic complex for low-temperature PTT (42–45 °C).…”

Section: In Vitro and In Vivo Potential Applications Of Hydrogelmentioning

confidence: 99%

Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity

Cao

Duan

Yan

et al. 2021

Sig Transduct Target Ther

428

256

View full text Add to dashboard Cite

Hydrogel is a type of versatile platform with various biomedical applications after rational structure and functional design that leverages on material engineering to modulate its physicochemical properties (e.g., stiffness, pore size, viscoelasticity, microarchitecture, degradability, ligand presentation, stimulus-responsive properties, etc.) and influence cell signaling cascades and fate. In the past few decades, a plethora of pioneering studies have been implemented to explore the cell–hydrogel matrix interactions and figure out the underlying mechanisms, paving the way to the lab-to-clinic translation of hydrogel-based therapies. In this review, we first introduced the physicochemical properties of hydrogels and their fabrication approaches concisely. Subsequently, the comprehensive description and deep discussion were elucidated, wherein the influences of different hydrogels properties on cell behaviors and cellular signaling events were highlighted. These behaviors or events included integrin clustering, focal adhesion (FA) complex accumulation and activation, cytoskeleton rearrangement, protein cyto-nuclei shuttling and activation (e.g., Yes-associated protein (YAP), catenin, etc.), cellular compartment reorganization, gene expression, and further cell biology modulation (e.g., spreading, migration, proliferation, lineage commitment, etc.). Based on them, current in vitro and in vivo hydrogel applications that mainly covered diseases models, various cell delivery protocols for tissue regeneration and disease therapy, smart drug carrier, bioimaging, biosensor, and conductive wearable/implantable biodevices, etc. were further summarized and discussed. More significantly, the clinical translation potential and trials of hydrogels were presented, accompanied with which the remaining challenges and future perspectives in this field were emphasized. Collectively, the comprehensive and deep insights in this review will shed light on the design principles of new biomedical hydrogels to understand and modulate cellular processes, which are available for providing significant indications for future hydrogel design and serving for a broad range of biomedical applications.

show abstract

Section: In Vitro and In Vivo Potential Applications Of Hydrogelmentioning

confidence: 99%

Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity

Cao

Duan

Yan

et al. 2021

Sig Transduct Target Ther

428

256

View full text Add to dashboard Cite

show abstract

“…Furthermore, nanocarriers have to be developed to enhance the local immune response, turning GBM “cold” tumors into “hot” tumors and therefore promoting the infiltration of immune cells. To do so, inducing ICD of GBM cell by using immunostimulant nanocarriers can facilitate the antitumor immune response and improve therapeutic effects [ 205 , 206 ]. In addition, new administration routes need to be explored.…”

Section: Limitations Of Current Preclinical Models and Future Outlook To Improve Combination Strategies For The Immunotherapy Of Gbmmentioning

confidence: 99%

Immunotherapy for glioblastoma: the promise of combination strategies

Bausart

Préat

Malfanti

2022

J Exp Clin Cancer Res

115

View full text Add to dashboard Cite

Glioblastoma (GBM) treatment has remained almost unchanged for more than 20 years. The current standard of care involves surgical resection (if possible) followed by concomitant radiotherapy and chemotherapy. In recent years, immunotherapy strategies have revolutionized the treatment of many cancers, increasing the hope for GBM therapy. However, mostly due to the high, multifactorial immunosuppression occurring in the microenvironment, the poor knowledge of the neuroimmune system and the presence of the blood−brain barrier, the efficacy of immunotherapy in GBM is still low. Recently, new strategies for GBM treatments have employed immunotherapy combinations and have provided encouraging results in both preclinical and clinical studies. The lessons learned from clinical trials highlight the importance of tackling different arms of immunity. In this review, we aim to summarize the preclinical evidence regarding combination immunotherapy in terms of immune and survival benefits for GBM management. The outcomes of recent studies assessing the combination of different classes of immunotherapeutic agents (e.g., immune checkpoint blockade and vaccines) will be discussed. Finally, future strategies to ameliorate the efficacy of immunotherapy and facilitate clinical translation will be provided to address the unmet medical needs of GBM.

show abstract

“…Not surprisingly, various locally applied hydrogel-based drug delivery systems have shown excellent therapeutic potential for local TME immunomodulation in gliomas [201,202], holding promise that this strategy may increase the delivery and efficacy of ITs for BCBMs. While investigations into hydrogels for BCBM IT delivery are just beginning to be reported, several groups have begun leveraging hydrogel technology to improve IT drug delivery in extracranial BC models.…”

Section: Hydrogel-based Drug Delivery Systems For Itmentioning

confidence: 99%

Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases

Carney

Pandey

Kapur

et al. 2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Brain metastases (BMs) are the most common type of brain tumor, and the incidence among breast cancer (BC) patients has been steadily increasing over the past two decades. Indeed, ~ 30% of all patients with metastatic BC will develop BMs, and due to few effective treatments, many will succumb to the disease within a year. Historically, patients with BMs have been largely excluded from clinical trials investigating systemic therapies including immunotherapies (ITs) due to limited brain penetration of systemically administered drugs combined with previous assumptions that BMs are poorly immunogenic. It is now understood that the central nervous system (CNS) is an immunologically distinct site and there is increasing evidence that enhancing immune responses to BCBMs will improve patient outcomes and the efficacy of current treatment regimens. Progress in IT for BCBMs, however, has been slow due to several intrinsic limitations to drug delivery within the brain, substantial safety concerns, and few known targets for BCBM IT. Emerging studies demonstrate that nanomedicine may be a powerful approach to overcome such limitations, and has the potential to greatly improve IT strategies for BMs specifically. This review summarizes the evidence for IT as an effective strategy for BCBM treatment and focuses on the nanotherapeutic strategies currently being explored for BCBMs including targeting the blood–brain/tumor barrier (BBB/BTB), tumor cells, and tumor-supporting immune cells for concentrated drug release within BCBMs, as well as use of nanoparticles (NPs) for delivering immunomodulatory agents, for inducing immunogenic cell death, or for potentiating anti-tumor T cell responses. Graphical abstract

show abstract

Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection

Cited by 205 publications

References 34 publications

Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity

Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity

Immunotherapy for glioblastoma: the promise of combination strategies

Harnessing nanomedicine for enhanced immunotherapy for breast cancer brain metastases

Contact Info

Product

Resources

About